BR112022018553A2 - Formulações de um agonista do receptor x farnesoide - Google Patents

Formulações de um agonista do receptor x farnesoide

Info

Publication number
BR112022018553A2
BR112022018553A2 BR112022018553A BR112022018553A BR112022018553A2 BR 112022018553 A2 BR112022018553 A2 BR 112022018553A2 BR 112022018553 A BR112022018553 A BR 112022018553A BR 112022018553 A BR112022018553 A BR 112022018553A BR 112022018553 A2 BR112022018553 A2 BR 112022018553A2
Authority
BR
Brazil
Prior art keywords
farnesoid
formulations
receptor agonist
pharmaceutical formulations
receptor
Prior art date
Application number
BR112022018553A
Other languages
English (en)
Inventor
D Smith Nicholas
Mansfield Robert
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of BR112022018553A2 publication Critical patent/BR112022018553A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULAÇÕES DE UM AGONISTA DE RECEPTOR FARNESOIDE X. São aqui descritas formulações farmacêuticas de um agonista do receptor farnesoide X, 4-((4-(1-(terc-butil)-1H-pirazol-4-il)piridin-2-il)((4-(4-metoxi- 3-metilfenil)biciclo[2.2.2]octan-1-il)metil)carbamoil)ciclohexil 3-hidroxiazetidina-trans-1-carboxilato e métodos de uso de tais formulações farmacêuticas no tratamento de condições, doenças ou distúrbios associados a atividade do receptor farnesoide X.
BR112022018553A 2020-03-18 2021-03-17 Formulações de um agonista do receptor x farnesoide BR112022018553A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991216P 2020-03-18 2020-03-18
PCT/US2021/022793 WO2021188695A1 (en) 2020-03-18 2021-03-17 Formulations of a farnesoid x receptor agonist

Publications (1)

Publication Number Publication Date
BR112022018553A2 true BR112022018553A2 (pt) 2022-11-29

Family

ID=75478197

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018553A BR112022018553A2 (pt) 2020-03-18 2021-03-17 Formulações de um agonista do receptor x farnesoide

Country Status (10)

Country Link
US (1) US20230120914A1 (pt)
EP (1) EP4121012A1 (pt)
JP (1) JP2023518398A (pt)
KR (1) KR20220155596A (pt)
CN (1) CN115666528A (pt)
AR (1) AR121597A1 (pt)
AU (1) AU2021239956A1 (pt)
BR (1) BR112022018553A2 (pt)
TW (1) TW202143962A (pt)
WO (1) WO2021188695A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004919A2 (pt) 2018-09-18 2021-06-01 Metacrine, Inc. agonistas de receptor farnesoide x e usos dos mesmos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037482A1 (en) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
AU2014320463B2 (en) * 2013-09-11 2018-08-02 Centre National De La Recherche Scientifique (Cnrs) Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
US20190062277A1 (en) * 2015-09-16 2019-02-28 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
US20200131129A1 (en) * 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7174709B2 (ja) * 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
JP7258763B2 (ja) * 2017-03-15 2023-04-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
CZ2017298A3 (cs) * 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
BR112021004919A2 (pt) * 2018-09-18 2021-06-01 Metacrine, Inc. agonistas de receptor farnesoide x e usos dos mesmos
CN113056270A (zh) * 2018-09-18 2021-06-29 梅塔科林公司 法尼醇x受体激动剂的结晶形式

Also Published As

Publication number Publication date
WO2021188695A1 (en) 2021-09-23
EP4121012A1 (en) 2023-01-25
AU2021239956A1 (en) 2022-10-13
CN115666528A (zh) 2023-01-31
TW202143962A (zh) 2021-12-01
JP2023518398A (ja) 2023-05-01
US20230120914A1 (en) 2023-04-20
KR20220155596A (ko) 2022-11-23
AR121597A1 (es) 2022-06-22

Similar Documents

Publication Publication Date Title
Perkins et al. Antinociceptive activity of the bradykinin B1 and B2 receptor antagonists, des-Arg9,[Leu8]-BK and HOE 140, in two models of persistent hyperalgesia in the rat
NO20061737L (no) Aminosubstituerte erylamino B2 adrenergiske receptoragonister
NO330981B1 (no) Indol- eller benzimidazolderivater for modulering av IkB-kinase, fremgangsmate for fremstilling av disse, legemiddel og anvendelse av forbindelsene
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
DE69414398D1 (de) Heterocyclische neurokinin-antagonisten
BRPI0409173A (pt) compostos e composições como inibidores de proteìna quinase
UY24560A1 (es) Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
HRP20050826B1 (hr) Ciklički inhibitori proteinske tirozin kinaze
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
NO331166B1 (no) Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene
IL178745A0 (en) Methods for treatment and management of scleroderma using 4-(amino)-2(2,6-dioxo(3-piperidyl))-isoindoline -1,3-dione
ES2128544T3 (es) Pirrolopirimidinas como antagonistas del crf.
ECSP056027A (es) Tratar desorden inmunológico usando agonistas de interleucina - 21/receptor de interleucina - 21.
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
AU2003287914A1 (en) Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor
GT200500020A (es) Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.
DE60318219D1 (de) PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]